Clinical trials: Non-Valvular Atrial Fibrillation
Stroke
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial…
- Trial name
- ASAP-TOO (NCT02928497)
- Testing
- WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
- Where
- 92 sites in United States, Belgium and 7 more
- Volunteers
- 481 people
- Sponsor
- Boston Scientific Corporation
Non-valvular Atrial Fibrillation
The CONFORMAL Early Feasibility Study
An evaluation of the safety and performance of the Conformal Left Atrial Appendage Seal for Left Atrial Appendage Occlusion
- Trial name
- NCT03616028
- Testing
- left atrial appendage closure
- Where
- 11 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Conformal Medical, Inc
Coronary Artery Disease, Atrial Fibrillation
A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin
The study aims to evaluate the safety and effectiveness comparisons between warfarin, dabigatran, and rivaroxaban in routine clinical practice among Japanese non-valvular atrial fibrillation (NVAF) patients with concomitant…
- Trial name
- NCT05051904
- Where
- Germany
- Volunteers
- 39,357 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Left Atrial Appendage Closure
China REgistry of WATCHMAN
This registry is designed to observe the safety and effectiveness of WATCHMAN left atrial appendage closure technology in a Chinese population.
- Trial name
- CREW (NCT03014557)
- Testing
- left atrial appendage closure device implantation
- Where
- China
- Volunteers
- 413 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Non-Valvular Atrial Fibrillation
Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela
To characterize treatment patterns and healthcare resource utilization among adults diagnosed with non-valvular atrial fibrillation (NVAF) from the private setting in Venezuela.
- Trial name
- NCT02756481
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in Belgium
The PROVECT study is a retrospective, multicentre study assessing the effectiveness and the safety outcomes in patients with non-valvular atrial fibrillation (NVAF) treated by apixaban between 2015 and 2019 (5 years follow up).
- Trial name
- PROVECT (NCT05116267)
- Where
- Belgium
- Sponsor
- Pfizer
Atrial Fibrillation
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as…
- Trial name
- SiERRA UK (NCT03847181)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin
- Where
- United Kingdom
- Volunteers
- 45,164 people
- Sponsor
- Bayer
Congestive Heart Failure Chronic, Atrial Fibrillation (Permanent)
Inflammation, Epigenetics in CHF Patients With AF
the goal of this case-control cross-sectional study is assessing in a cohort of patients with CHF and permanent AF The serum levels of some candidate cytokine variables and their relationship with some selected metabolic…
- Trial name
- NCT07152301
- Where
- Italy
- Volunteers
- 164 people
- Sponsor
- University of Palermo
Atrial Fibrillation, Heart Diseases
Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis
Atrial fibrillation (AF) is more common in patients with renal disease compared to the general population an risk increase to as much as 10 times in patients on hemodialysis (HD).
- Conditions
- Atrial Fibrillation, Heart Diseases, Renal Disease, Bleeding
- Trial name
- WATCH-HD (NCT03446794)
- Testing
- Non Intervention
- Where
- 20 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Fundación EPIC
Atrial Fibrillation
Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Some people can develop an abnormal heart beat known as "Atrial fibrillation" or "AF" that puts them at risk of developing clots in the heart.
- Trial name
- EMANATE (NCT02100228)
- Testing
- Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
- Where
- 165 sites in United States, Belgium and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Pfizer
Atrial Fibrillation
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
This is a prospective and open label study that aims to enroll approximately 1200 patients with non-valvular atrial fibrillation (NVAF) not previously treated with Pradaxa® and free of gastrointestinal symptoms (GIS) for at least…
- Trial name
- NCT01493557
- Testing
- pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal
- Where
- 103 sites in United States, Canada
- Volunteers
- 1,067 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation
The investigators hypothesize that earlier initiation of edoxaban in AF-related stroke patients may significantly reduce the early recurrence of ischemic stroke, compared with conventional strategy of anticoagulation following…
- Trial name
- NCT03433235
- Testing
- Edoxaban
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Jong Sung Kim
Atrial Fibrillation
Pattern of Non Valvular Atrial Fibrillation in Acute Ischemic Stroke Patients at Assiut University Hospitals
Pattern of non valvular Atrial fibrillation in acute ischemic stroke patients at Assiut University Hospitals.
- Trial name
- NCT04097132
- Testing
- echocardiography
- Where
- Egypt
- Volunteers
- 1 people
- Sponsor
- Assiut University
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- BRONCE-AP (NCT02559232)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 247 people
- Sponsor
- Bayer
Atrial Fibrillation
The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage
The objective is to assess the safety and effectiveness of new dabigatran and warfarin patients diagnosed with NVAF in the US DoD population.
- Trial name
- NCT02043808
- Where
- United States
- Volunteers
- 25,586 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Assessing the Safety and Efficacy of the LAmbre™ Plus Device
Randomized controlled trial assessing the safety and efficacy of the LAmbre Plus LAA Closure System to rescue the risk of thromboembolism in patients with non-valvular AF.
- Trial name
- REDUCE-AF (NCT06465706)
- Testing
- LAmbre investigational device
- Volunteers
- 1,826 people
- Sponsor
- Kansas City Heart Rhythm Research Foundation
Acute Ischemic Stroke, Atrial Fibrillation
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
The goal of this clinical trial is to compare the safety and effectiveness of anticoagulation combined with antiplatelet therapy in acute ischemic stroke (AIS) patients with concomitant non-valvular atrial fibrillation (NVAF) and…
- Conditions
- Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid, Intracranial Atherosclerosis
- Trial name
- ALLY (NCT06058130)
- Testing
- Anticoagulant Oral, Anticoagulation combined with antiplatelet therapy
- Where
- 2 sites in China
- Volunteers
- 2,171 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Valvular Heart Disease
RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
RIvaroxaban for Valvular heart diseasE and atRial fibrillation trial (RIVER trial).
- Trial name
- NCT02303795
- Testing
- Rivaroxaban, Warfarin
- Where
- Brazil
- Volunteers
- 1,005 people
- Sponsor
- Hospital do Coracao
Combined Pulsed-field Ablation (PFA)
Combined Pulsed-field Ablation (PFA) and Left Atrial Appendage Occlusion Using Watchman Flx or Amulet
AF ablation is an established treatment option for non-valvular atrial fibrillation (NVAF). While AF ablation helps to maintain cardiac rhythm in sinus, the stroke risk associated with AF persists after ablation.
- Trial name
- COMPAWA (NCT05560204)
- Testing
- Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO)
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Non Valvular Atrial Fibrillation
LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System for Patients With Non-Valvular Atrial Fibrillation
Worldwide, atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. The prevalence of AF gradually increases with age; its prevalence is 0.5% ~ 0.8% among 45 ~ 59 year-olds, 1.8% ~ 5.9% among 60 ~ 69 year-olds…
- Trial name
- LAmbre2 (NCT07455539)
- Testing
- LAmbre II Left Atrial Appendage Occluder
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong